Clinical Trial Update: A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab plus ipilimumab with guadecitabine versus nivolumab plus ipilimumab in melanoma and non-small cell lung cancer resistant to a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Guadecitabine (guadecitabine)
• IPI (ipilimumab)
• NIVO (nivolumab)

Snippet

Sponsor: Italian Network for Tumor Biotherapy Foundation | Conditions: Melanoma, Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN